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Summary
 
Mice rendered deficient for interleukin (IL) 6 by gene targeting were evaluated for their re-
sponse to T cell–dependent antigens. Antigen-specific immunoglobulin (Ig)M levels were un-
affected whereas all IgG isotypes showed varying degrees of alteration. Germinal center reac-
tions occurred but remained physically smaller in comparison to those in the wild-type mice.
This concurred with the observations that molecules involved in initial signaling events leading
to germinal center formation were not altered (e.g., B7.2, CD40 and tumor necrosis factor
R1). T cell priming was not impaired nor was a gross imbalance of T helper cell (Th) 1 versus
Th2 cytokines observed. However, B7.1 molecules, absent from wild-type counterparts, were
detected on germinal center B cells isolated from the deficient mice suggesting a modification
of costimulatory signaling. A second alteration involved impaired de novo synthesis of C3 both
in serum and germinal center cells from IL-6–deficient mice. Indeed, C3 provided an essential
stimulatory signal for wild-type germinal center cells as both monoclonal antibodies that inter-
rupted C3-CD21 interactions and sheep anti–mouse C3 antibodies caused a significant de-
crease in antigen-specific antibody production. In addition, germinal center cells isolated from
C3–deficient mice produced a similar defect in isotype production. Low density cells with den-
dritic morphology were the local source of IL-6 and not the germinal center lymphocytes.
Adding IL-6 in vitro to IL-6–deficient germinal center cells stimulated cell cycle progression
and increased levels of antibody production. These findings reveal that the germinal center
produces and uses molecules of the innate immune system, evolutionarily pirating them in or-
der to optimally generate high affinity antibody responses.
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I
 
nterleukin 6 exerts its effects on many biological systems
(1, 2). It is responsible for mediating the production of
acute phase proteins (3, 4), fever (5), and release of hor-
mones (6) in response to injury or infection. In hemato-
poiesis, IL-6 appears to potentiate the action of other fac-
tors such as GM-CSF and M-CSF (7, 8). As a growth and
differentiation factor, IL-6 has been used for optimal pro-
duction of B cell hybridomas and mouse plasmacytomas
(9–11). This wide spectrum of activities is largely due to
the numerous cell types that produce IL-6 including, but
not limited to, fibroblasts (12, 13) endothelial cells (13),
macrophages (11), T cells (11, 14), and B cells (15). Its pro-
duction is regulated by several cytokines including IL-1,
IL-2, IL-3, IL-4, IL-13, 
 
g
 
-IFN, TNF and platelet-derived
growth factor as well as LPS, calcium ionophore, and vi-
ruses (1, 16). IL-6 exerts its effect through a receptor com-
posed of the restricted IL-6 receptor chain (IL-6R) and a
common signal transducer, gp130 (17).
Dysregulation of IL-6 is associated with several patho-
logical states. These include cachexia, lymphomas, multiple
myeloma, psoriasis, osteoporosis, rheumatoid arthritis, and
Castleman’s disease (18). In many of these conditions, in-
creased levels of IL-6 cause an overproduction of antibody
contributing significantly to the clinical pathology. This re-
lationship is supported by two transgenic models in which
overproduction of IL-6 leads to splenomegaly and hyper-
gammaglobulinemia (19, 20). Similarly, transferring preB
cells derived from IL-6 transgenic mice into Rag 2-defi-
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cient or SCID mice results in significantly more IgG and
IgA production than with wild-type preB cells (21).
Previously, it has been reported that IL-6–deficient mice
are impaired in their ability to mount an acute phase re-
sponse as well as control the infections of vaccinia virus and
 
Listeria monocytogenes
 
 (4). To further investigate the role of
IL-6 in humoral immunity, deficient mice were immu-
nized with a T cell dependent antigen. During antibody re-
sponses, naive antigen-specific B cells are initially activated
in the outer T cell zones or follicular borders via interac-
tions with dendritic cell primed T cells (22–26). Some then
enter follicular dendritic cell (FDC)
 
1
 
 networks where they
acquire the ability to effectively process and present antigen
(27–29). To date, the various gene-targeted mice have
shown that this initial interaction between B cells and FDC
must occur in order to initiate germinal center formation
(30, 31). In combination with costimulatory molecules, the
subsequent presentation of peptide to local antigen-specific
T cells results in the delivery of signals producing a germi-
nal center (25, 30, 32). Expansion, hypermutation and im-
munoglobulin switch mechanisms are activated (33, 34).
Selection of high affinity B cells presumably occurs while
noncompetitive low affinity cells are left to die by apoptosis
(35, 36). The consequences of these events are the genera-
tion of high affinity and immunoglobulin switched mem-
ory B and preplasma cells (37).
The importance of complement during T cell–depen-
dent antibody responses was first demonstrated long before
the advent of gene-targeted mice (38, 39). The use of de-
pleting agents identified a role for C3 in follicular localiza-
tion of antigen as well as induction of T-dependent anti-
body production (38, 40–42) and the local synthesis of C3
was documented in lymphoid tissues (43, 44). Antibodies
to mouse C3 were found to inhibit T cell–dependent anti-
body production in vitro (44) and furthermore comple-
ment dependent mixed aggregation of different lymphoid
cell types was reported (45). Much more recently, studies
in genetically deficient mice have provided further detailed
information about the role of C3 as these mice have a re-
duced but not totally impaired ability to form germinal
centers and mount antigen-specific antibody responses (46,
47). In addition, using these mice, Carroll and colleagues
have shown that wild-type bone marrow–derived mac-
rophages corrected the knock out phenotype by providing
local C3 production (48).
These observations are significant because as we show
here, in addition to several more subtle effects, IL-6–defi-
cient mice have impaired local production of C3. Further-
more, germinal center cells isolated from IL-6– and from
C3-deficient mice have a comparable defect in IgG2a and
IgG2b antibody production. We propose that the produc-
tion of IL-6 and of C3 is linked as part of the highly coor-
dinated events occurring locally within germinal centers to
insure the generation of high affinity antibodies.
 
Materials and Methods
 
Mice, Antigen, and Immunization.
 
IL-6–deficient mice were
generated by homologous recombination as described elsewhere
(4). C3-deficient mice were obtained from M.C. Carroll (Har-
vard Medical School, Boston, MA; reference 47). All mice were
housed under specific pathogen-free conditions. Wild-type (i.e.,
littermate) control, IL-6–deficient (129sv 
 
3
 
 C57BL/6 or C57BL/6),
or C3-deficient (C57BL/6) mice were used between 8 and 16
wk of age. Mice were immunized with either OVA or DNP-
OVA both precipitated in alum (49).
For ascertaining serum antibody titers, mice were immunized
with 100 
 
m
 
g/ml DNP-OVA intraperitoneally (0.2 ml), subcuta-
neously in each of the two rear limbs (0.05 ml/site) and intra-
nuchally (0.1 ml). 14 d later, blood samples were collected. For a
secondary response, at day 14 after a primary injection, the mice
were given the same immunization protocol and blood samples
were collected 10 d later. For the isolation of antigen-specific T
cells or germinal center cells, mice were immunized as above
with OVA and the cells isolated from the draining lymph nodes
on day 7.
 
Measurement of Antibody Titers by ELISA.
 
DNP-specific anti-
bodies were detected by an ELISA using standard procedures.
Goat anti–mouse IgG1, IgG2a, IgG2b, IgG3, IgM antibodies
(Southern Biotechnology Associates, Birmingham, AL), and the
rat anti–mouse IgE antibody, EM95.3, (provided by Z. Eshhar,
The Weizmann Institute of Science, Rehovot, Isreal; reference
50) were used for revealing isotype-specific serum antibodies.
The relative antibody concentrations in the serum and superna-
tant samples of Figs. 1 and 7 
 
B
 
, respectively, correspond to the
dilution at OD 50%.
 
Immunohistology and Morphometric Analysis.
 
Spleens and lymph
nodes were take from mice before and at various times after im-
munization. Serial cryosections were prepared, fixed in acetone
for 10 min stored in airtight containers at 
 
2
 
20
 
8
 
C. For determina-
tion of germinal center volume, the lymph nodes were entirely
sectioned (e.g., 30–40 serial sections) from 3 mice per time point
(i.e., day 8, 12 and 15 after primary immunization) and then in-
cubated with the plant lectin, peanut agglutinin (PNA), a reagent
that localizes germinal center cells in situ (51). The PNA was ob-
tained biotinylated (Vector Laboratories Inc., Burlingame, CA)
and revealed using streptavidin-peroxidase (Vectastain Elite ABC;
Vector Laboratories, Inc.). All peroxidase reactions were devel-
oped using diaminobenzidine (1 mg/ml; Sigma Chemical Co.,
St. Louis, MO) containing 0.1% H
 
2
 
O
 
2
 
.
Once serial sections were processed, 8–12 germinal centers of
each time point were photographed from beginning to end using
a Zeiss axiophot microscope. Using the photographs, the longest
axis of the x and y plane were measured and the volume calcu-
lated using the equation: volume of an ellipse 
 
5 
 
4/3
 
p
 
abc
 
 (where
 
a
 
 and 
 
b
 
 are the two-dimensional measurements taken from the
photos and 
 
c
 
 is the value obtained by calculating the number of
photographs the germinal center was present in and multiplying
this by the section thickness). The values obtained for the wild-
type were in agreement for those previously published (52).
 
T Cell Proliferation and Cytokine Production.
 
T cells were ob-
tained from spleens of mice 7 d after a primary immunization
with OVA. After lysis of red blood cells with a hypertonic solu-
tion, cells were layered into a discontinuous gradient. The cells in
 
1
 
Abbreviations used in this paper:
 
 BCR, B cell antigen receptor; FDC, folli-
cular dendritic cell; HA, hemagglutinin; HPRT, hypoxanthine phospho-
ribosyltransferase; PNA, peanut agglutinin; RT, reverse transcription. 
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bands corresponding to densities of 
 
.
 
1.080 g/ml were harvested.
The preparation was further enriched for CD4
 
1
 
 cells by depleting
other cells types with antibody coated magnetic beads (Dyna-
beads; Dynal, Oslo, Norway). Specifically, the MHC class II
 
1
 
cells were negatively selected using the mAb, M5/114 (American
Tissue Culture Collection, Rockville, MD), and the CD8
 
1
 
 cells
using the mAb, 53.6.78 (PharMingen, San Diego, CA). APC
were obtained from spleens after lysis of red blood cells and de-
pletion of CD4
 
1
 
 and CD8
 
1
 
 cells using GK1.5 (PharMingen) or
53.6.78 mAb-coated magnetic beads, respectively. The APC
were irradiated with 30Gy then placed at 2 
 
3
 
 10
 
5
 
 cells per well in
round-bottom 96-well plates. T cells were added at a concentra-
tion of 2 
 
3
 
 10
 
5
 
 cells per well in the presence or absence of OVA
as indicated in Fig. 3 
 
A
 
 or at 10 
 
m
 
g/ml for Fig. 3 
 
B
 
. For the pro-
liferation assay, cells were cultured for 4 d and 
 
3
 
[H]thymidine
added for the final 18 h. For the detection of cytokines, cells were
cultured for 48 h, the supernatants harvested and the levels of
 
g
 
-IFN and IL-5 assessed using cytokine ELISA kits (Genzyme
Corp., Boston, MA).
 
Isolation of Germinal Center Cells.
 
Germinal center cells were
isolated from the lymph nodes of mice 7 d after a primary immu-
nization with OVA or DNP-OVA according to the procedure
described elsewhere (53). In brief, the low density, nonadherent
cells were obtained using: (
 
a
 
) an enzyme cocktail to digest the
collagen, allowing embedded cell types including FDC to be re-
leased from the stroma (collagenase, No. 4188; Worthington
Biomedical Corp., Freehold, NJ; deoxyribonuclease I; Sigma
Chemical Co.); (
 
b
 
) a continuous Percoll gradient to obtain the
1.060–1.065 g/ml density cells; and (
 
c
 
) a 1-h adherence step at
37
 
8
 
C to remove the adherent cells such as macrophages and den-
dritic cells. The resulting population has previously been shown
to have the following features: contains 
 
.
 
75% B cells, 10% T
cells, 10% FDC, and 
 
,
 
5% TBM; both antigen-specific prolifera-
tion and antibody production of IgG and IgE isotypes occurs; and
within 24 h of culture, the B cells form clusters around FDC that
are dependent on both the presence of FDC and T cells (53).
 
Flow Cytometry.
 
The level of CD80 (B7.1) and CD86 (B7.2)
expression on germinal center B cells was determined using flow
cytometry. For this, isolated germinal center cells were incubated
with the PE-labeled CD45RA antibody (B220; clone 14.8;
PharMingen) and either the biotinylated hamster anti–mouse
CD80 (clone 16-10A1; PharMingen) or CD86 mAb (clone GL1;
PharMingen) revealed using FITC-Streptavidin (Southern Bio-
technology Associates, Inc.). A gate was established for the B220
positive cells and then the amount of CD80 and CD86 deter-
mined.
 
C3 Measurement.
 
Mouse serum C3 concentrations were mea-
sured by electroimmunoassay calibrated with standards based on
isolated pure murine C3, as previously described (54).
 
Reverse Transcription PCR for C3.
 
Total cellular RNA was
prepared from isolated germinal center cells above using Trizol
 
TM
 
(GIBCO BRL, Gaithersburg, MD). Random hexamer-primed
reverse transcription (RT) was performed with Superscript-RT
(GIBCO BRL) using one quarter of total RNA obtained in a 25-
 
m
 
l
reaction volume containing 0.04 u (1.2 ng) random hexamers
(Pharmacia Biotech, Inc., Piscataway, NJ), 0.4 mM dNTP
(Promega Corp., Madison, WI) 50 mM Tris-HCl, pH 8.3, 75 mM
KCL, 3 mM MgCl
 
2
 
, and 0.5 units RNAsin (Promega Corp.). Af-
ter 90 min of incubation at 37
 
8
 
C, samples were heated at 94
 
8
 
C
and then quickly chilled on ice. cDNA samples were diluted to
100 
 
m
 
l with H
 
2
 
O and 1 to 2 
 
m
 
l used for PCR. Cycling condi-
tions for PCR amplification of the complement 3 alpha chain
using specific oligonucleotides C3for2257:TGCGTGAACAA
CACAGAAGAG and C3rev2764: AAGGGGACAATGACAT-
ACGG were 94
 
8
 
C for 1 min before 35 cycles of 94
 
8
 
C for 20 s,
58
 
8
 
C for 30 s, and 72
 
8
 
C for 30 s, followed by a final extension at
72
 
8
 
C for 5 min. cDNA samples were standardized by competitive
PCR for expression of 
 
b
 
2-microglobulin using a mimic control
vector essentially as described (55).
 
Antibody Inhibition Assay.
 
Germinal center cells were isolated
at day 7 after a primary injection of OVA. Cells were placed in
round-bottom 96-well plates at 3 
 
3
 
 10
 
5
 
 cells per well in the pres-
ence or absence of 10 
 
m
 
g/ml 7G6 (rat IgG2b anti–mouse com-
plement receptors 1 and 2 mAb; provided by T. Kinoshita, Osaka
University Medical School, Osaka, Japan; reference 56) or 10
 
m
 
g/ml FDC-M1 (rat IgG2b anti–mouse isotype control mAb;
reference 53). In addition, the cells were also incubated in the
presence of 10 
 
m
 
g/ml affinity-purified F(ab
 
9
 
)
 
2
 
 fragments of the
IgG1 fraction of a monospecific polyclonal sheep anti–mouse C3
antiserum (W23); reference 44) or sheep IgG1 (as the isotype
control). After 7 d, the supernatants were harvested and the levels
of OVA-specific IgG1 and IgG2a determined as stated above.
 
RT-PCR for IL-6.
 
Semiquantitative RT-PCR was performed
as described elsewhere (57, 58). cDNA was quantified by PCR
using HPRT (hypoxanthine phosphoribosyl-transferase) as a
cDNA reference. A Biometra TRIO-thermoblock thermal cycler
was used for all PCRs, operating on a regime of 96
 
8
 
C for 6 s,
45
 
8
 
C (for IL-6) or 55
 
8
 
C (for HPRT) for 15 s, 72
 
8
 
C for 60 s, for
31 cycles, followed by 72
 
8
 
C for 10 min. PCR reactions were of
15 
 
m
 
l, using cDNA derived from an estimated 20 cells for HPRT
standardization and 100 cell equivalents for IL-6 (57, 58).
The cDNA from the following cell populations were assessed
for IL-6 mRNA expression: positive control, concanavalin A
stimulated splenocytes; clusters, germinal center cells cultured for
24 h to form aggregates and then the aggregates collected using
sedimentation over a 30% FCS gradient for 1 h; FDC sorted, iso-
lated germinal center cells were labeled with the rat anti–mouse
FDC mAb, FDC-M1, followed by a mouse anti–rat IgG F(ab
 
9
 
)
 
2
 
conjugated to fluorescein (Jackson ImmunoResearch Laborato-
ries, Inc., West Grove, PA) then FDC-M1 positive cells were ob-
tained by sorting on a FACScan
 
Ò
 
. Because of the fragile nature of
their elongated dendritic processes, FDC tend to not do well
passing through the FACScan
 
Ò
 
. As such, in order to obtain
enough material, the positive cells were directly sorted into a so-
lution of 5.5 M guanidinium thiocyanate, 25 mM sodium citrate
and 0.5% sodium lauroyl sarcosine (Pharmacia Biotech, Inc.);
FDC irrad, a second way to enrich for FDC is to irradiate mice 2 d
after the secondary challenge with 6Gy (Cesium source; reference
59). This exposes dividing cells to damaging amounts of irradia-
tion, significantly decreasing lymphocytes in the preparation (49).
The FDC were obtained from the irradiated mice using the same
protocol for germinal center cells, yielding a purity of 50% FDC;
T cell– and B cell–sorted, isolated germinal center cells were la-
beled with the rat anti–mouse thy1 T24) or rat anti–mouse B220
(14.8) mAbs followed by a mouse anti–rat IgG F(ab
 
9
 
)
 
2
 
 conjugated
to FITC (Jackson ImmunoResearch Laboratories, Inc.) in order
to obtain germinal center T cells or B cells, respectively, by sort-
ing on a FACScan
 
Ò
 
.
 
Immunohistochemistry for IL-6.
 
IL-6 protein was localized on
acetone fixed cryosections of immunized lymph nodes. For this,
the tissue was pretreated in PBS containing 0.05% saponin and all
washing steps and dilutions of reagents were carried out using this
solution. Endogenous peroxidase activity was blocked using
0.01% H
 
2
 
O
 
2 
 
in PBS. The sections were then subjected to the avi-
din-biotin blocking kit according to the manufacturer’s specifica-
tions (No. SP-2001; Vector Laboratories Inc.). The anti-IL-6– 
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specific mAb, clone MP5-20F3 (PharMingen), was applied to the
sections for 2 h followed by a biotinylated rabbit anti–rat IgG
(mouse absorbed; No. BA-4001; Vector Laboratories Inc.) for 30
min. On a serial section, the FDC network was localized using
the rat anti–mouse FDC mAb, FDC-M1, followed by a mouse
anti–rat IgG F(ab
 
9
 
)
 
2
 
 conjugated to biotin (Jackson ImmunoRe-
search Laboratories, Inc.). Both the anti-IL-6 and anti-FDC mAbs
were revealed with the Vector ABC kit in conjunction with di-
aminobenzidine (1 mg/ml) containing 0.1% H
 
2
 
O
 
2
 
.
 
 
 
The sections
were counterstained using methyl green.
 
Proliferation and Antigen-specific Antibody Production.
 
Germinal
center cells were isolated 7 d after a primary immunization and
placed in round-bottom 96-well plates at a density of 3 
 
3
 
 10
 
5
 
cells per well. Recombinant IL-6 was added (200 U/ml; Phar-
Mingen) at the initiation of the cultures. For the proliferation assay,
 
3
 
[H]thymidine was added after 48 h of culture and the plates har-
vested 24 h later. For determination of antibody production, the
supernatants were harvested after 7 d of culture. The supernatants
were then assayed for antigen-specific antibody isotypes using the
ELISA methods outlined above.
 
Results
 
Antigen-specific Serum Antibody Titers Are Altered in IL-6–
deficient Mice.
 
The role of IL-6 during humoral responses
was initially evaluated by testing the level of various iso-
types produced after injection of the T cell–dependent an-
tigen, DNP-OVA. As shown in Fig. 1 
 
A
 
, whereas the
amount of IgM produced was comparable to wild-type
controls after a primary injection, the level of IgG was im-
paired. IgG1 was least affected being reduced only two- to
threefold whereas IgG2a and IgG2b were more dramati-
cally influenced. For the 129sv 
 
3
 
 C57BL/6 background,
IgG2a levels were decreased between 10- and 1,000-fold
while in the C57BL/6 background, the decrease was lim-
ited to 10–20-fold. IgG2b was less strain dependent, de-
creasing between 10–50-fold independent of the genetic
background. The large range in antigen-specific IgG2a ti-
ters using the mixed 129sv 
 
3
 
 C57BL/6 background was
also observed in the wild-type littermate controls (Fig. 1, 
 
A
 
and 
 
B
 
).
After secondary antigen challenge, the IL-6–deficient
mice presented yet another profile. IgM, IgG1, and IgE ti-
ters were comparable or slightly higher than the wild-type
controls (Fig. 1 
 
B
 
). The levels of IgG2a and IgG2b re-
mained low and IgG3 was also minimal. In addition, after
both the primary and secondary immunizations, the total
amount of specific immunoglobulin produced was 10-fold
less in the deficient mice as assessed using anti-kappa re-
agents demonstrating that the inability to produce normal
levels of antibody was not compensated by other isotypes
(data not shown).
 
Absence of IL-6 Results in Impaired Germinal Center Devel-
opment.
 
Since the serum titers for the high affinity iso-
types were the most dramatically affected, the ability to
form germinal centers was evaluated. Preparing lymph
nodes from mice 5, 7, 9, 12, and 15 d after a primary im-
munization with DNP-OVA, a reduction in the size of the
area labeled with PNA was observed in IL-6–deficient
mice (Fig. 2 
 
A) as compared with the controls (Fig. 2 B).
Morphometric analysis of these tissues revealed that while
the average volume of the PNA positive foci was similar at
day 7 (wild-type 5 2.1 3 1026 mm3 versus IL-6–deficient
mice 5 2.0 3 1026 mm3), by day 9, the average volume of
the germinal centers was diminished (Fig. 2 C). In the ab-
sence of IL-6, the cells did not create germinal centers large
enough to easily observe the classical light and dark zones.
Labeling with the rabbit anti–mouse polyclonal antibody,
Ki67 (31), revealed that the germinal center cells were in
cycle (data not shown). In addition, although tingible body
macrophages and apoptosis were still observed in these ar-
eas, the absolute number of TBM were reduced similar to
the decrease in germinal center volume (data not shown).
As such, it did not appear that increased apoptosis or an in-
ability to proliferate were directly affected by the lack of
IL-6. Instead, it could be argued that the cells exited the
germinal center prematurely possibly due to a lack of re-
sponsiveness to events mediated downstream of an IL-6
signal.
As it was observed that at day 7 after antigen injection
the histology of germinal centers in lymph nodes of wild-
type and IL-6–deficient were similar, subsequent experi-
ments used cells isolated at day 7 to attempt to dissect the
processes involved for the phenotype produced.
T Cell Priming Is Not Affected in IL-6–deficient Mice. To
rule out the possibility that a direct effect within the T cell
compartment occurred in IL-6–deficient mice, the number
of antigen-specific T cells was determined. Using a bulk
culture assay (i.e., T cells isolated 7 d after a primary immu-
nization cultured with APC in the presence of antigen),
Figure 1. Antigen-specific serum antibody titers are lowered in the ab-
sence of IL-6. Wild-type (closed circles) and IL-6–deficient (open circles) 129 3
C57BL/6 mice were bled 14 d after the primary (A) and 10 d after the
secondary (B) immunization with DNP-OVA. The DNP- (shown here)
and OVA- (not shown) specific isotype titers were determined using stan-
dard ELISA techniques. Each symbol represents an individual mouse.1899 Kopf et al.
similar amounts of 3[H]thymidine were incorporated by
the T cells isolated from the deficient and wild-type mice
(Fig. 3 A). This result was confirmed using a limiting dilu-
tion assay showing that the number of antigen-specific IL-3
producing cells was 110 versus 125 per 106 cells in deficient
and wild-type control mice, respectively (data not shown).
To address T cell cytokine profiles, T cells were also cul-
tured for 48 h with APC plus antigen and the supernatant
used to determine levels of g-IFN and IL-5 (Th1 versus
Th2 profile, respectively). As can be seen in Fig. 3 B, no
gross difference in levels of cytokines produced by the acti-
vated T cells was observed although the IL-5 (and IL-4,
data not shown) levels were consistently elevated by two-
fold in the IL-6–deficient mice.
Alteration of Cell Surface B7.1 but not B7.2 Expression Oc-
curs in the Absence of IL-6. To determine the role of IL-6
specifically on germinal center cells, the low buoyant den-
sity, nonadherent population of lymph node cells were ob-
tained 7 d after a primary immunization with DNP-OVA.
As reported previously (53), this population of cells mimics
many of the characteristics attributed to the germinal center
cells in vivo. It consists of 5–10% antigen bearing FDCs,
75–80% B cells, 5–10% T cells and ,5% TBM. They
spontaneously form clusters within 24 h of culture and ex-
hibit antigen-specific B cell proliferation and antibody pro-
duction.
RNA species encoding proteins that appear to be essen-
tial for the formation of germinal centers such as B7.2 (60,
61), CD40 (62), and TNF-R1 (63) were present in the
freshly isolated day 7 populations correlating with the abil-
ity to initiate the formation of PNA1 foci (data not
shown). However, the mRNA levels for B7.1 were slightly
higher in the IL-6–deficient mice derived cells than the
wild-type (data not shown). This led to the investigation of
protein production for these costimulatory molecules. As
can be seen in Fig. 4, whereas both germinal center B cell
populations expressed similar amounts of B7.2, only those
obtained from the IL-6–deficient mice expressed B7.1
molecules. These data suggest that under normal condi-
tions, the signals which exist (at day 7) within the germinal
center support a T cell phenotype promoted by B7.2.
However, in the absence of IL-6, B7.1 is also expressed,
potentially causing a premature signal for downregulating
the response (64).
Figure 2. Germinal center size
is limited in IL-6–deficient mice.
Lymph nodes from wild-type and
IL-6–deficient mice were iso-
lated at day 9, 12, and 15 after
primary immunization with
DNP-OVA and prepared for im-
munohistochemistry. Using PNA
as the marker for germinal cen-
ters, 30–40 serial sections were
labeled (brown) and single germi-
nal centers morphometrically ana-
lyzed to determine their volume.
A and B show the average size of
a germinal center in the IL-6–
deficient (A) versus the wild-type
(B) mice at day 9 after immuniza-
tion (PNA labeled area outlined
with black lines). Magnification 3250. C shows the cumulative data of the analysis (open circles, deficient mice; solid circles, wild-type mice). The data rep-
resents the analysis of 6–8 complete germinal centers from a total of 3 mice for each time point. Error bars represent the standard deviation.
Figure 3. Analysis of T cell priming and cytokine production in IL-6–
deficient mice. T cells were isolated from wild-type (solid bars) or IL-6–
deficient (open bars) mice at day 7 after primary immunization with OVA.
(A) the T cells were culture with irradiated APC in the presence or ab-
sence of various OVA concentrations. 3[H]thymidine was added on the
third day of culture for 8 h. The data are representative of triplicate wells 6
SD. (B) The T cells were restimulated with irradiated APC in the pres-
ence of OVA for 48 h. The supernatants were collected and the cytokine
levels determined by standard ELISA procedures. Triplicate wells were as-
sessed and the data is expressed as relative units between deficient and the
control wild-type mice 6 SD.
Figure 4. Expression of B7.2 is simi-
lar while B7.1 is upregulated on germi-
nal center B cells of IL-6–deficient as
compared with wild-type mice. Germi-
nal center cells were isolated as de-
scribed in the Materials and Methods
section. The B cells were gated on using
B220 conjugated to PE and then the
level of B7.1 (A) and B7.2 (B) deter-
mined using biotinylated reagents plus
avidin-FITC. The results are presented
as levels on the wild-type derived (solid
histograms) versus germinal center B cells
obtained from the deficient mice (open
histograms). Isotype controls were simi-
lar to the level seen with B7.1 on wild-
type derived cells.1900 Interleukin 6 in Germinal Centers and Antibody Responses
IL-6–deficient Mice Demonstrate Altered C3 Responses After
Antigenic Stimulation. Activation products of C3 are known
to interact with complement receptor 2 (CR2; CD21) mol-
ecules and augment B cell activation in conjunction with the
coligation of the B cell antigen receptor (BCR; references
65, 66). As IL-6 plays a central role in the induction of acute
phase protein synthesis, including C3, C3 levels were deter-
mined in serum taken before and at 1, 2 and 6 d after antigen
injection. The results demonstrated that C3 levels were sig-
nificantly elevated in wild-type mice when responding to an
immunogen (Fig. 5 A). However, IL-6–deficient mice did
not show a deviation from steady state levels.
Although failure to upregulate serum C3 levels correlated
with impaired humoral immunity in IL-6–deficient mice,
the circulating C3 concentration was still normal and cer-
tainly sufficient for any complement-dependent function
taking place in the plasma. This suggested that if C3 was
involved it must be C3 within the lymphoid tissue micro-
environment, and specifically the germinal centers in which
the interactions productive of the T dependent immune
response take place between antigen, presenting cells and
lymphocytes. The original studies of immunosuppression
produced by cobra venom factor and its abrogation by pas-
sively administered anti-cobra factor antibodies, provided
evidence for just this important local role of C3 within re-
sponding lymphoid tissue (40, 41). Indeed, analyzing the
levels of mRNA for C3 in the germinal center cells isolated
at day 7 revealed a strong band from the wild-type mice (Fig.
5 B). In contrast, the germinal center cells from the IL-6–
deficient mice showed a reduction of C3 specific transcripts.
Next, to investigate specifically what a lack of C3 would
cause in our system, wild-type germinal center cells were
cultured in the presence or absence of an anti-CD21 mAb
(7G6) or F(ab9)2 fragments of an anti-mouse C3 Ab
(W23). Supernatants obtained from these cultures demon-
strated that both abs inhibited antigen-specific IgG2a and
IgG2b titers by 50–80% (Fig. 5 C and data not shown).
Thus, local C3 is at least part of the mechanism for optimal
germinal center function.
IL-6 Production Lies within the Nonlymphocytic Cells of the
Germinal Center. To determine which cells produce IL-6
in germinal centers, extracts from various wild-type germi-
nal center cell populations were obtained and analyzed for
levels of IL-6 mRNA. The low buoyant density, nonad-
herent fraction was obtained from the lymph nodes of im-
mune mice and either immediately FACSÒ sorted to obtain
highly purified B or T cells for RNA (Fig 6, B CELL
SORTED and T CELL SORTED), or placed in culture to
allow the formation of FDC-B cell-T cell clusters. After 24 h,
the clusters were separated from the single cells in the cul-
tures then prepared for RNA (Fig. 6, CLUSTERS). As
FDC are difficult to obtain in a highly purified form, the
following strategy was used. As previously reported, in or-
der to enrich for FDC, 48 h after a secondary immuniza-
tion mice were subjected to 6Gy of gamma irradiation (49).
The lymph nodes were then excised 48 h later and the low
buoyant density, nonadherent fraction now containing
,5% lymphocytes (as compared with 80–90% without ir-
radiation treatment) and #50% FDC were obtained and
the RNA extracted (Fig. 6, FDC IRRAD). To further en-
rich for FDC, this preparation was double labeled with an
anti-Ig reagent and the anti-FDC mAb, FDC-M1. The
double positive cells consisting of .80% FDC were FACSÒ
sorted and the RNA extracted (Fig. 6, FDC SORTED).
The results demonstrate that IL-6 mRNA is produced
by cells within the germinal center clusters (Fig. 6 A). The
dissection of the various fractions revealed it was not the
lymphocytes, but the FDC-enriched populations that pro-
duced the IL-6 mRNA. Furthermore, using a bioassay for
IL-6 extended these results demonstrating that IL-6 was
present only in cultures containing either clusters or the
FDC irradiated population but not in the sorted T or B
lymphocytes (data not shown). Immunohistochemistry
performed on cryosections from immune wild-type mice
confirmed these results revealing that a subset of cells with
dendritic morphology (Fig. 6 B) within the FDC network
(Fig. 6 C) produced IL-6. This production was limited to
active germinal centers and not detected in primary follicles
(data not shown).
Exogenous IL-6 Augments Proliferation and Antibody Produc-
tion by Germinal Center B Cells from IL-6–deficient Mice.
When germinal center cells were isolated from wild-type
Figure 5. C3 production and
mRNA levels are altered in re-
sponse to antigen challenge in
IL-6–deficient mice and block-
ing C3-CD21 interactions be-
tween germinal center cells re-
sults in decreased antibody
production. (A) Sera were ob-
tained from wild-type (solid cir-
cles) and IL-6–deficient (open cir-
cles) mice at various times before
and after immunization. The C3
levels were determined and the
data representative of three mice
per group 6 SD. (B) Germinal
center cells were purified from
wild-type or IL-6–deficient
groups of mice (n 5 4) at day 7
after immunization as described
in Materials and Methods and C3
mRNA expression was analyzed
by semiquantitative RT-PCR.
Samples were standardized for
the expression of b2 microglob-
ulin (b2 m) using a competitor
plasmid (55). As a positive con-
trol for C3 expression, liver
RNA of wild-type mice was ob-
tained 24 h after injection of sil-
ver nitrate for induction of an
acute phase response. Lane 1, wild-type germinal center cells; lane 2, IL-
6–deficient germinal center cells; lane 3, positive control from liver. (C)
Germinal center cells were isolated from wild-type mice at 7 d after pri-
mary immunization with OVA and incubated for 7 d in the presence or
absence of 7G6 (anti-CD21), FDC-M1 (isotype control), W23 (anti-C3),
or sheep IgG1 (isotype control). OVA specific antibody titers were deter-
mined for IgG1 and IgG2a using standard ELISA procedures. The data is
represented as percent inhibition as compared with wells with medium
alone, done in triplicates 6 SD.1901 Kopf et al.
mice and cultured with additional IL-6, no effect was
observed (Fig. 7). This most likely reflects that optimal
stimulation already exists within the wild-type derived
population. In contrast, germinal center cells isolated from
IL-6–deficient mice responded significantly to exogenous
IL-6 with both increases in DNA synthesis (Fig. 7 A) and
antigen-specific antibody production (Fig. 7 B). These ob-
servations suggest that IL-6 plays a role in cell cycle pro-
gression that influences the ability to differentiate along the
plasmacytoid pathway (67).
Germinal Center Cells Isolated from C3-deficient or IL-6–
deficient Mice Have Similar Defects in Antibody Production. It has
been previously shown that C3-deficient mice have im-
paired germinal center formation and defects in antigen-
specific antibody production (47). To further correlate the
phenotype observed in the IL-6–deficient germinal center
cells with a role for C3, the antigen-specific antibody iso-
types were compared between IL-6–deficient and C3-defi-
cient mice. As shown in Fig. 7 B, whereas C3-deficient
mice can mount an IgG1 response, IgG2a and IgG2b titers
were equally affected in both targeted mice.
Discussion
IL-6 signaling via its two subunit receptor (the IL-6 re-
ceptor chain and gp130) mediates numerous biological ac-
tivities. To understand the role of IL-6 in high affinity anti-
body responses, we concentrated on the cells of the
germinal center. Our initial observations demonstrated that
in IL-6–deficient mice antigen-specific antibody titers and
the development of germinal centers were impaired. These
effects are consistent with a report concerning mice over-
expressing a dominant negative form of gp130, the signal-
transducing element for IL-6 as well as other cytokines
such as IL-11, oncostatin M and leukemia inhibitory factor
(68, 69). These mice have severely lowered antibody titers.
However, in IL-6–deficient mice, the IgG2a and IgG2b re-
sponses were most affected and IgE responses were slightly
enhanced rather than decreased revealing more specifically
the influence of IL-6 itself on antibody responses. The IgE
levels also suggested that IL-4 production was not im-
paired. Indeed, T cell activation and T helper cell subset
differentiation appeared not to be significantly altered in
IL-6–deficient mice. Interestingly, IgE antibody formation
is suppressed by in vivo complement depletion (70), indi-
cating the existence of differing pathways for induction of
the different T-dependent isotypes. In vitro restimulation
Figure 6. FDC produce IL-6
in germinal centers. (A) mRNA.
Germinal center cells were
isolated from wild-type mice
as specified in Materials and
Methods. T cells, B cells and
FDC were either further sepa-
rated by flow cytometry using
the markers, Thy-1, B220, and
FDC-M1, respectively (T
CELL SORTED, B CELL
SORTED and FDC SORTED)
or cultured overnight in order to
form clusters (CLUSTERS).
FDC were also isolated from im-
mune mice 2 d after receiving
6Gy of irradiation (FDC irrad). A Th2 cell line was used as the positive control (1VE CONTROL). Embryonic stem cells were used as a negative control
(ES CELLS). RNA was prepared and the level of message for IL-6 determined using RT-PCR. HPRT was used as control for sample loading. (B and
C) Cryosections were processed from lymph nodes of wild-type mice at day 10 after primary immunization for immunoperoxidase labeling (brown). The
germinal center localization of IL-6–producing cells (B) was revealed in the light zone using the anti-mouse IL-6 mAb, MP5-20F3, whereas the adjacent
sections demonstrate the extent of the FDC network in this corresponding area using the anti-mouse FDC labeling mAb, FDC-M1 (C).
Figure 7. IL-6 augments proliferation and antibody production by ger-
minal center cells in vitro. (A) germinal center cells were isolated from
wild-type and IL-6–deficient mice 7 d after primary immunization. The
germinal center cells were cultured in the presence (hatched areas) or ab-
sence (open areas) of IL-6 for 72 h and 3[H]thymidine added for the final
24 h. The data represent triplicates 6 SD. (B) germinal center cells iso-
lated from wild-type, IL-6–deficient, or C3-deficient mice were cultured
in the presence or absence of IL-6 (as indicated on the figure) for 7 d and
the supernatants then assayed for antigen-specific antibody titers using
standard isotype ELISA procedures. The figure shows representative data
from 1 of 3 experiments in which 3–5 mice per group were pooled.1902 Interleukin 6 in Germinal Centers and Antibody Responses
of primed T cells with irradiated APCs in the presence of
antigen showed similar levels of antigen-specific T cells and
Th1 responses (g-IFN production), whereas Th2 responses
(IL-4, IL-5) were slightly elevated. Our results imply that
in vivo Th1 and Th2 development does not depend on
IL-6, although in vitro IL-6 may favor the induction of a
Th2 phenotype (reference 71; Kopf, M., unpublished ob-
servations).
During humoral responses, our data demonstrates that
IL-6 appears to act on germinal center B cells directly via
the IL-6R and gp130, and indirectly by promoting the
production of C3 in the local environment. Germinal cen-
ter B cells are known to express IL-6 receptors but, unlike
other B cells, lack the ability to make the cytokine (Fig. 6
A; reference 15). It appears that this is the role of a subset of
low density cells with dendritic morphology. As critical
events occur in this microenvironment to produce a high
affinity immunoglobulin molecule, a stepwise series of
events ensures checkpoints to minimize autoreactivity (72).
Certainly, the sensitivity of germinal center reactions to de-
ficiencies in numerous molecules supports this view of
multistep and multicellular mechanisms (30, 31). It is inter-
esting then that the expression of B7.1 is detected at day 7
on cells from the deficient mice and not on those of the
wild-type. Although the phenotype of B7.1 and B7.2
single and double deficient mice would suggest these
molecules have some overlapping effects (61), clearly over-
expressing B7.1 demonstrated a negative regulatory modi-
fication of humoral responses (64). Hence, a more specific
evaluation of the role of these two molecules in germinal
center responses using these sets of mice would be of interest.
C3 contributes to the germinal center response by (a)
forming complexes with antibody and antigen that are
trapped on the plasma membrane of FDC (73, 74); and (b)
providing optimal B cell stimulation via ligation of CD21
(the complement receptor type 2 [CR2], a part of the
CD19-CD21-CD81 complex; references 75–77). It has
long been known that spleen cells produce C3 and that
anti-C3 antibodies can inhibit T-dependent antibody pro-
duction (39, 44). Carroll and colleagues have recently
shown that myeloid cells within lymphoid tissues are re-
sponsible for this local C3 production and that it is regu-
lated by responses to antigen (48). Our data concerning C3
mRNA expression in germinal center cells and its regula-
tion by IL-6 are novel and for the first time link these
events. Further evidence of this relationship is found by
comparing the phenotype observed in the IL-6– and C3-
deficient germinal center cells (Fig. 7). Another possible
candidate for regulation of local C3 levels could be g-IFN
(78, 79). However, as we did not find any difference in
g-IFN production by T cells isolated from wild-type versus
IL-6–deficient mice, this appears not to be the mechanism.
Thus, C3 plays a central role in generating high affinity an-
tibody responses and our data would suggest that IL-6 plays
a role in initiating these events.
It is relevant to also compare the IL-6–deficient mice
with the phenotypes published for the C3- and CD21-defi-
cient mice (46, 47). They are the only genetically engi-
neered mice published to date that show a reduced but not
totally ablated germinal center development (30, 59). Un-
fortunately, in these studies, individual IgG isotypes were
not reported. In our study, both anti-C3 and anti-CD21
neutralizing antibodies inhibited IgG2a and IgG2b produc-
tion by the germinal center cell cultures, whereas only anti-
CD21 inhibited IgG1. This may reflect the difference in
blocking a receptor that has multiple ligands versus neutral-
izing a single ligand. In addition, the more diverse effect
could be related to interfering with the CD19-CD21-
CD81 complex (75). Our results using the antibodies were
confirmed using the C3-deficient mice (Fig. 7) and thus
show the utility of analyzing immunoglobulin isotypes in
order to define more precisely the role of molecules during
humoral responses.
It is well known that the effects of the complement sys-
tem can be overcome by altering the dose of antigen, the
site of the immunization and the type of adjuvant (39, 56,
80, 81). Similarly, the requirement of IL-6 for humoral re-
sponses appears not to be an absolute. For instance, IL-6–
deficient mice infected with M. tuberculosis show slightly
enhanced (twofold) rather than reduced specific serum an-
tibody titers 3 mo after infection (82). Furthermore, IL-6–
deficient mice with systemic candidiasis produce elevated
levels of Candida-specific IgG2a antibody compared with
control IL-6 wild-type mice (83). However, IL-6–deficient
mice are highly susceptible to infection with both M. tubercu-
losis and C. albicans. Numbers of yeast cells or mycobacteria
in infected organs are #100-fold increased in the absence of
IL-6. In contrast, IgG2a responses after infection with Plas-
modium chabaudi were strongly impaired in IL-6–deficient
mice (Langhorne, J., and M. Kopf, unpublished data).
Studies of mucosal responses in IL-6–deficient mice have
revealed what appeared to be conflicting results regarding
the role of IL-6 in the regulation of IgA. IL-6–deficient
mice infected intranasally with recombinant vaccinia virus
expressing the hemagglutinin (HA) glycoprotein of influ-
enza virus have strongly reduced numbers of HA-specific
IgA and IgG antibody-producing cells (84). Likewise, in-
traduodenal injection of ovalbumin resulted in impaired
IgA responses (84). In contrast, normal mucosal IgA and
IgG responses were observed in IL-6–deficient mice after
either inoculation with Helicobacter felis or repeated peroral
immunization with soluble protein (ovalbumin) in the
presence of cholera toxin (CT; reference 85). Our present
results may help to resolve this conflict. The defective pri-
mary response against HA expressed by attenuated vaccinia
virus probably reflects complement dependence, whereas
the response against repeated antigen immunization in the
presence of the strong adjuvant such as CT, or a high infec-
tion dose with H. felis, does not require complement. Our
results show that the primary response against ovalbumin
was more affected than after the secondary challenge (Fig.
1), and that a tertiary response eventually showed little dif-
ferences, again suggesting that with multiple insults, path-
ways exist to circumvent the loss of one pathway.
A model incorporating these and the recent findings of
others would involve the early induction of de novo C31903 Kopf et al.
synthesis by IL-6 in order to permit attachment of immune
complexes to FDC and possibly also to activate naive B
cells with low affinity immunoglobulin receptors, both in-
trinsic steps of germinal center development. One potential
source for early IL-6 production could be the antigen stim-
ulated dendritic cells (86). As they migrate through mac-
rophage rich zones in order to reach the T cell areas (87),
these cells may induce local myeloid C3 production. Later,
during the dynamic processes occurring in germinal cen-
ters, FDC would receive appropriate signals to produce
IL-6 that may amplify local C3 production by tingible
body macrophages as well as directly act on germinal cen-
ter B cells via IL-6–sensitive transcription factors. These
scenarios clearly demonstrate the complicated nature of
the events occurring to generate high affinity antibody re-
sponses.
Signaling of CD21 expressed by B cells via C3 compo-
nents is essential then for normal germinal center reactions
(88). It has also been demonstrated that C3 must be in a
form that is able to cross-link CD21 (e.g., on the surface of
FDC), as soluble C3 stimulates the proliferation of acti-
vated, but not resting, B cells (89). Interestingly, a novel
C3 mRNA transcript has been identified that enhances B
cell proliferation (90). The mechanism of action then for
IL-6 concerning the increased thymidine uptake in our
germinal center B cell-T cell-FDC cultures could be the
generation of this C3 protein locally. The experiments ad-
dressing these issues are ongoing. In addition, the conse-
quences of IL-6 production locally within the germinal
center may be to act on centoblasts directly via transcrip-
tion factors and cyclin-dependent kinases (2, 67). Indeed
the increase of antigen-specific antibody that occurred
when exogenous IL-6 was added to the IL-6–deficient ger-
minal center cell cultures exemplifies the role of IL-6 in
differentiation and cell cycle control of late stage B cells
(20, 89, 91).
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